2023
Coffee, adenosine, and the liver
Dranoff J. Coffee, adenosine, and the liver. Purinergic Signalling 2023, 20: 21-28. PMID: 37755557, PMCID: PMC10828332, DOI: 10.1007/s11302-023-09968-5.Peer-Reviewed Original ResearchCoffee as chemoprotectant in fatty liver disease: caffeine-dependent and caffeine-independent effects
Dranoff J. Coffee as chemoprotectant in fatty liver disease: caffeine-dependent and caffeine-independent effects. AJP Gastrointestinal And Liver Physiology 2023, 324: g419-g421. PMID: 36976807, DOI: 10.1152/ajpgi.00026.2023.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsLiver diseaseLiver-related mortalityChronic liver diseaseFatty liver diseasePositive health outcomesPrimary active ingredientCoffee consumptionEpidemiological studiesHealth outcomesAdenosine receptorsBiological plausibilityDiseaseActive ingredientsPatientsAntagonistMortalityRecent publicationsReceptors
2022
Proteomics Indicates Lactate Dehydrogenase Is Prognostic in Acetaminophen-Induced Acute Liver Failure Patients and Reveals Altered Signaling Pathways
Vazquez JH, Kennon-McGill S, Byrum SD, Mackintosh SG, Jaeschke H, Williams DK, Lee WM, Dranoff JA, McGill MR, Group A. Proteomics Indicates Lactate Dehydrogenase Is Prognostic in Acetaminophen-Induced Acute Liver Failure Patients and Reveals Altered Signaling Pathways. Toxicological Sciences 2022, 187: 25-34. PMID: 35172013, PMCID: PMC9216044, DOI: 10.1093/toxsci/kfac015.Peer-Reviewed Original ResearchConceptsAcute liver failureEnd-stage liver diseaseALF patientsLactate dehydrogenaseLiver diseaseDay 1Acute Liver Failure Study GroupAcute liver failure patientsTransplant-free survivorsKing's College criteriaLiver failure patientsMost clinical laboratoriesFailure patientsLiver failurePrognostic valueControl volunteersAlanine aminotransferaseStudy groupPrognostic potentialPeak injuryDay 3Good biomarkerDay 1 samplesNonsurvivorsPatientsShort‐Term Safety of Repeated Acetaminophen Use in Patients With Compensated Cirrhosis
McGill MR, James LP, McCullough SS, Moran JH, Mathews SE, Peterson EC, Fleming DP, Tripod ME, Vazquez JH, Kennon‐McGill S, Spencer HJ, Dranoff JA. Short‐Term Safety of Repeated Acetaminophen Use in Patients With Compensated Cirrhosis. Hepatology Communications 2022, 6: 361-373. PMID: 34558847, PMCID: PMC8793989, DOI: 10.1002/hep4.1810.Peer-Reviewed Original ResearchConceptsAPAP-protein adductsAcetaminophen useCirrhosis groupClinical outcomesDay 5Sensitive biomarkerAdverse clinical outcomesShort-term administrationCompensated cirrhosisLiver injuryAPAP administrationLiver damagePK analysisCurrent guidelinesStudy initiationCirrhosisTerm safetyDay 1Day 3APAP metabolitesHigh dosesPatientsPilot studyAPAPLonger treatment
2017
Coffee Consumption and Prevention of Cirrhosis: In Support of the Caffeine Hypothesis
Dranoff JA. Coffee Consumption and Prevention of Cirrhosis: In Support of the Caffeine Hypothesis. Gene Expression 2017, 18: 1-3. PMID: 28893365, PMCID: PMC5885142, DOI: 10.3727/105221617x15046391179559.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2015
I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis
Feld JJ, Lavoie ÉG, Fausther M, Dranoff JA. I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis. F1000Research 2015, 4: 95. PMID: 25977756, PMCID: PMC4416533, DOI: 10.12688/f1000research.6368.2.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsChronic liver diseaseSalutary effectsLiver diseaseLiver fibrosisHepatocellular carcinomaNovel pharmacologic treatmentsCoffee ingestionPharmacologic treatmentFibrosis pathogenesisObservational studyRegular ingestionCoffee consumptionEpidemiological dataPharmacological effectsCaffeine consumptionCirrhosisDecaffeinated coffeeCaffeine effectsEffector moleculesPatientsFibrosisPathogenesisDiseaseIngestionConsistent effectI drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis
Feld J, Lavoie É, Fausther M, Dranoff J. I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis. F1000Research 2015, 4: 95. DOI: 10.12688/f1000research.6368.1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsChronic liver diseaseSalutary effectsLiver diseaseLiver fibrosisHepatocellular carcinomaNovel pharmacologic treatmentsCoffee ingestionPharmacologic treatmentFibrosis pathogenesisObservational studyRegular ingestionCoffee consumptionEpidemiological dataPharmacological effectsCaffeine consumptionCirrhosisDecaffeinated coffeeCaffeine effectsEffector moleculesPatientsFibrosisPathogenesisDiseaseIngestionConsistent effect